Welcome to Strike Pharma! Using proprietary Adaptable Drug Affinity Conjugate (ADACTM) technology, we aim to take precision medicine to a new level, enabling development of individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor. Such highly targeted treatments offer the potential to increase therapeutic efficacy and reduce dosage levels thereby minimizing the risk of side effects.
To date, development of immunotherapeutic cancer treatment has mainly focused on identifying subtle differences present in the tumor microenvironment with the aim of creating a single entity, such as a peptide or antibody, that can be used to stimulate an immune response. However, efficient, targeted delivery and in vivo stability have largely been ignored leading to limited success in the clinic. At Strike Pharma we aim to overcome these challenges.
Recent News & Events
Strike Pharma and FyoniBio conclude successful cell line development of Strike’s bi-specific antibody and clinical lead candidate
FyoniBio to present data at PEGS Boston 2023
Strike Pharma presents latest developments at AACR 2023
Chief Scientific Officer, Associate Professor Sara Mangsbo, presented some of the latest data demonstrating progress in the development of the ADAC technology platform for precision cancer immunotherapy.
Funds awarded to study ADAC™ technology in depth
Research to be supported by Cancerfonden, one of Sweden’s largest financiers of cancer research
Strike Pharma continues expansion of management team
Joacim Elmén appointed as Director, CMC
Strike Pharma and FyoniBio sign Master Service Agreement
Agreement covers Cell Line Development for a novel bi-specific therapeutic mAb
Strike Pharma’s Chief Scientific Officer receives BiotechBuilders Award 2022
Dr. Sara Mangsbo acknowledged for entrepreneurship and her contribution to Swedish life science industry